Yipinhong Pharmaceutical Co.Ltd(300723) (300723) the annual performance forecast for 2021 released on the evening of January 10 shows that the company expects to realize the net profit attributable to the shareholders of the listed company in 2021 of 293-361 million yuan, a year-on-year increase of 30% – 60%, and the net profit attributable to the shareholders of the listed company after deducting non recurring profits and losses of 197-240 million yuan, a year-on-year increase of 35% – 65%.
Yipinhong Pharmaceutical Co.Ltd(300723) said in the announcement that during the reporting period, the company’s revenue from self-developed products increased rapidly and its profitability improved steadily. The main products of the company increased rapidly. During the reporting period, the income of the company’s leading products such as clindamycin hydrochloride palmitate dispersible tablets, Qinxiang Qingjie oral liquid and Fuganlin oral liquid increased rapidly; The company’s new products brought revenue growth. During the reporting period, the company obtained 10 products such as ambroxol hydrochloride drops and levocetirizine hydrochloride oral drops and 12 drug (RE) registration approvals. With the gradual launch of each product on the market, it has made a positive contribution to the company’s revenue.
In addition, the company’s innovative R & D projects were gradually implemented, and the strategic transformation was accelerated. During the reporting period, the company’s subsidiary Ruiao biological investment controlled South China vaccine and entered the field of biological vaccine medicine; Ruiteng biological, a subsidiary, increased its capital to take shares in the world’s leading innovative drug R & D company Arthrosi, and cooperated in the development of anti gout drug ar882 and anti-tumor drug ar0 Guangfa Xinde Ruiteng venture capital industry fund, a subsidiary of Lianrui pharmaceutical, strategically takes shares in Wuhan Hanhai new enzyme Biotechnology Co., Ltd., China’s leading biomedical special enzyme industrialization company.
(source: China Securities Journal · China Securities Network)
